Drug intelligence / Profile preview

sufentanil + lidocaine

Development stage
Unknown
Lead developer
Centre Hospitalier Universitaire de Montpellier
Modality
Small Molecules
Administration
Intracardiac Injection, Intravascular Injection
01

Overview

sufentanil + lidocaine is a combination pharmacological protocol used for feticide during late-term termination of pregnancy (after 22 weeks' gestation). This protocol, utilized as a standard-of-care control in clinical research by the University Hospital, Montpellier, involves the sequential or combined administration of sufentanil and lidocaine. Sufentanil, a potent synthetic opioid, acts as a mu-opioid receptor agonist to provide fetal analgesia and sedation. Lidocaine, a local anesthetic, acts as a sodium channel blocker that inhibits the depolarization of cardiac myocytes (primarily via SCN5A), leading to rapid fetal cardiac asystole. The combination is typically administered via ultrasound-guided umbilical vein puncture or direct intracardiac injection to ensure fetal death prior to the induction of labor, addressing legal and ethical requirements for late-term terminations.

Other names
sufentanil + lidocaine-University Hospital, Montpellier-termination of pregnancysufentanil and lidocainesufentanil + lidocaine protocol
02

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on sufentanil + lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sufentanil + lidocaine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call